Neurological Autoimmune Diseases
Myasthenia Gravis
Targeted Removal of Autoantibodies
In myasthenia gravis, autoantibodies attack the acetylcholine receptors at the neuromuscular junction, disrupting the communication between nerves and muscles.
Through immunoadsorption, these pathogenic antibodies can be selectively removed from the blood, often leading to a noticeable improvement in muscle strength and fatigue within just a few days.
Evidence-based recommendation according to ASFA Category II (2023).
Neuromyelitis Optica Spectrum Disorder
(NMOSD)
This rare inflammatory disease of the central nervous system is caused by antibodies directed against aquaporin-4.
Immunoadsorption therapy can selectively remove these antibodies from the bloodstream, helping to reduce the severity and frequency of relapses.
Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP)
In treatment-resistant cases of CIDP, immunoadsorption can be used as an adjunct to IVIG or corticosteroid therapy to lower autoantibody levels and improve nerve conduction and clinical symptoms.
Apheresis treatment for neurological disorders does not always need to be performed in a hospital.
Depending on your diagnosis, overall health, and the physician’s evaluation, the therapy can often be carried out safely and comfortably on an outpatient basis at a specialized apheresis center.